RVPH Investor Alert: Rosen, Leading Investor Advisor,

NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation into potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) arising from allegations that Reviva Pharmaceuticals may have provided materially misleading business information to investors passed on publicly.

SO WHAT: If you have purchased Reviva Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Rosen Law Firm is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24451 or call Phillip Kim, Esq. at. Call us toll-free at 866-767-3653 or email [email protected] for class action information.

WHAT IS THIS ABOUT: On April 15, 2024, Reviva Pharmaceuticals filed a Current Report on Form 8-K with the SEC. In this recent report, Reviva Pharmaceuticals announced that “the Company’s previously published financial statements for the fiscal year ended December 31, 2022 are included in its Annual Report on Form 10-K, including interim financial statements for the quarterly period ended September 30, 2022 ended.” in its quarterly report on Form 10-Q and each of the interim financial statements for the quarterly periods in fiscal year 2023 included in its quarterly reports on Form 10-Q (collectively, the “Restatement Periods”) should be restated to correct for historical errors “correcting” relate primarily to the timing of the recognition of the Company’s estimated reserves for certain research and development costs and should therefore no longer be relied upon.”

On this news, Reviva Pharmaceuticals stock price fell $0.21 per share, or 5.69%, to close at $3.48 on April 15, 2024.

WHY ROSEN LAW: We encourage investors to select qualified advisors who have a track record of success in leadership roles. Companies issuing notices often do not have comparable experience, resources, or significant peer recognition. Many of these firms do not conduct securities class actions. Be wise when choosing your advisor. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest settlement ever in a securities class action lawsuit against a Chinese company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services in 2017 for number of securities class action settlements. The firm has been ranked in the top four every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

For updates, follow us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a similar result.

—————–

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com